← Back to Search

SGLT2 Inhibitor

Mizagliflozin for Post-Bariatric Hypoglycemia

Phase 2
Waitlist Available
Research Sponsored by Vogenx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-6 hours following liquid meal
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety and effects of mizagliflozin, a medication taken by mouth, on blood sugar levels in patients who have low blood sugar after bariatric surgery. Mizagliflozin has shown potential in improving chronic constipation.

Eligible Conditions
  • Post-Bariatric Hypoglycemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-6 hours following liquid meal
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-6 hours following liquid meal for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glucose Nadir After Mizagliflozin Dosing
Secondary study objectives
MMTT insulin concentration
MMTT plasma glucose concentration
MMTT time to peak insulin concentration after mizagliflozin dosing
+3 more

Side effects data

From 2023 Phase 2 trial • 9 Patients • NCT05541939
25%
Abdominal distension
25%
Nausea
25%
Diarrhoea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment Arm B Period 2 (10.0 mg Capsule)
Treatment Arm B Period 1 (2.5 mg Liquid Formulation)
Treatment Arm A Period 1 (2.5 mg Capsule)
Treatment Arm A Period 2 (5.0 mg Capsule)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment Arm BExperimental Treatment1 Intervention
Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)
Group II: Treatment Arm AExperimental Treatment1 Intervention
Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mizagliflozin
2022
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Vogenx, Inc.Lead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top